MedTrace Logo

18F-FDG PET/CT and Molecular Tumor Characterisation for Staging and Follow-up of Colon Cancer

NCT01636674 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 66

Last updated 2012-07-10

No results posted yet for this study

Summary

The investigators are investigating the usefulness of 18F-Fluordeoxyglucose Positron Emission Tomography/ Computed Tomography (18F-FDG PET/CT) for staging and follow-up of colon cancer. Furthermore, the investigators combine 18F-FDG PET findings with clinical and histopathological features, circulating tumor cell (CTC) analyses, tumor gene expression and measurements of circulating cancer biomarkers sUPAR, TIMP-1 and CEA in order to predict tumor recurrence.

The investigators hypothesis: The combination of functional imaging by 18F-FDG PET/CT and pre-existing and evolving molecular biomarkers will optimize tumor characterization, staging of disease and early detection of recurrence.

Conditions

Interventions

OTHER

18F-fluordeoxyglucose positron emission tomography/ computed tomography

18F-fluordeoxyglucose positron emission tomography/ computed tomography for preoperative staging and post-operative follow-up

Sponsors & Collaborators

  • University of Copenhagen

    collaborator OTHER

  • Rigshospitalet, Denmark

    collaborator OTHER

  • Region Zealand

    collaborator OTHER

  • Naestved Hospital

    lead OTHER

Principal Investigators

  • Bodil E Engelmann, MD · Naestved Hospital

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-07-31
Primary Completion
2013-03-31
Completion
2013-03-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01636674 on ClinicalTrials.gov